Business
Spectral and Somagen announce Canadian Distribution Agreement for Rapid West Nile Virus Test
Spectral and Somagen announce Canadian Distribution Agreement for Rapid West Nile Virus Test.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\nTORONTO, June 1 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI), a developer\nof innovative rapid diagnostic technologies, today announced an agreement with\nSomagen Diagnostics Inc., a leading supplier of in vitro diagnostic\ntechnologies, to distribute Spectral's Rapid West Nile Virus Test in the\nCanadian Market.\nThis product represents a major breakthrough in the ability to rapidly\nassess the many patients suspected of infection by West Nile Virus (WNV). The\nability to make the diagnosis for an individual patient with potential WNV\ninfection in less than an hour will allow doctors and public health personnel\nto intervene faster and more effectively manage the complications of WNV\ninfection, including meningoencephalitis. To date, Spectral's WNV diagnostic\nis the only rapid test intended for individual patient by patient application\nat the time of their presentation.\n\"We are very excited about this new relationship. Somagen's experience\nand coverage of the Canadian healthcare market is well suited to maximizing\nsales of the rapid WNV test.\", stated Robert Verhagen, Spectral's Vice\nPresident of Business Development.\n\"The addition of the Spectral West Nile Virus test complements our\ncurrent product offerings and we are looking forward to working with Spectral\nto offer this timely test to Canadian healthcare facilities.\", added Tammie\nKovacs, Vice President at Somagen.\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral provides accurate and timely information to\nclinicians enabling the early initiation of appropriate and targeted therapy.\nCurrent products include Spectral's rapid West Nile Virus (WNV) assay and its\nFDA approved rapid diagnostic for sepsis (the Endotoxin Activity Assay), as\nwell as a range of other biological reagents. Spectral's common shares are\nlisted on The Toronto Stock Exchange: SDI.\n\nSomagen Diagnostics Inc. is a leading supplier of in vitro diagnostic\ntechnologies to the Canadian Market. Somagen's focus is on providing superior\nlevels of value and service with products that are relevant and make a\nsignificant impact on the overall health of Canadians through better and\nfaster diagnosis and improved patient management.\n\nInformation in this news release that is not current or historically\nfactual information may cons...